# BIOATLA, INC. (BCAB) · Edgar & Edgarette company card

> Bioatla (BCAB) reported revenue of $0 million in FY2021, operating margin -32147% against a -15.8% median for biological products, (no diagnostic substances), equity 82.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1826892 · fiscal year ended 2021-12-31 · 1 audited years read · [page](https://www.pops4.com/boards/company/BCAB) · [JSON](https://www.pops4.com/boards/company/BCAB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $300,000 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -32146.7% |
| Net margin | -31800.7% |
| Operating cash flow | −$62M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $245M |
| Long-term debt | — |
| Total assets | $254M |
| Total equity | $211M |
| Equity ÷ assets | 82.9% |
| Return on equity | -45.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.01 (safe zone)
- Health Harbor boat: Old boat · three warning signs · filed restructuring or exit costs in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$48.2M in FY2025)

## Edgarette's reading

Exposure: revenue $300K (FY2021). Experience: one year on record; operating margin -32146.7%. Soundness: equity 82.9% of assets, return on equity -45.3%. Credibility: one audited year, little weight. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -32146.7% against a -15.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-08-28 ([filing](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002373/0001539497-26-002373-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-03-02 ([filing](https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/0001539497-26-000812-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-09-29 ([filing](https://www.sec.gov/Archives/edgar/data/1826892/000119312526407817/0001193125-26-407817-index.htm))

## Recent filings

- S-1 · filed 2026-10-20 · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002711/0001539497-26-002711-index.htm)
- 8-K · filed 2026-10-20 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000119312526425553/0001193125-26-425553-index.htm)
- 8-K · filed 2026-09-29 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000119312526407817/0001193125-26-407817-index.htm)
- 8-K · filed 2026-08-28 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002373/0001539497-26-002373-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000119312526349542/0001193125-26-349542-index.htm)
- 8-K · filed 2026-07-16 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1826892/000119312526306117/0001193125-26-306117-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001826892.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1826892

## Cite

POPS4, Edgar & Edgarette: BIOATLA, INC. (BCAB) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BCAB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2021, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.